Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
📈 **POSITIVE** • High confidence analysis (89%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business